179 related articles for article (PubMed ID: 18652658)
1. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.
Zidek W; Schrader J; Lüders S; Matthaei S; Hasslacher C; Hoyer J; Bramlage P; Sturm CD; Paar WD
Cardiovasc Diabetol; 2008 Jul; 7():22. PubMed ID: 18652658
[TBL] [Abstract][Full Text] [Related]
2. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.
Zidek W; Schrader J; Lüders S; Matthaei S; Hasslacher C; Hoyer J; Zemmrich C; Bramlage P; Sturm CD; Paar WD
Cardiovasc Diabetol; 2012 Jan; 11():1. PubMed ID: 22230104
[TBL] [Abstract][Full Text] [Related]
3. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
4. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
5. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
6. First-line diuretics versus other classes of antihypertensive drugs for hypertension.
Reinhart M; Puil L; Salzwedel DM; Wright JM
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD008161. PubMed ID: 37439548
[TBL] [Abstract][Full Text] [Related]
7. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.
Jamerson KA
Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S24-30. PubMed ID: 10986156
[TBL] [Abstract][Full Text] [Related]
8. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
[TBL] [Abstract][Full Text] [Related]
9. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
Reboldi G; Gentile G; Angeli F; Verdecchia P
Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
[TBL] [Abstract][Full Text] [Related]
10. Choice of antihypertensive treatment in subjects with pre-diabetes. Is there a dream after the navigator.
Eleftheriadou I; Tsioufis C; Tsiachris D; Tentolouris N; Stefanadis C
Curr Vasc Pharmacol; 2011 Nov; 9(6):715-22. PubMed ID: 21470107
[TBL] [Abstract][Full Text] [Related]
11. [Corner points of antihypertensive therapy in prediabetic state. Success with a combination].
MMW Fortschr Med; 2003 Jul; 145(27-28):53. PubMed ID: 14587192
[No Abstract] [Full Text] [Related]
12. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
Nazarzadeh M; Bidel Z; Canoy D; Copland E; Wamil M; Majert J; Smith Byrne K; Sundström J; Teo K; Davis BR; Chalmers J; Pepine CJ; Dehghan A; Bennett DA; Smith GD; Rahimi K;
Lancet; 2021 Nov; 398(10313):1803-1810. PubMed ID: 34774144
[TBL] [Abstract][Full Text] [Related]
13. What have we learned from the current trials?
Abbott KC; Bakris GL
Med Clin North Am; 2004 Jan; 88(1):189-207. PubMed ID: 14871059
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive drugs: diuretics and betablockers are the best assessed.
Prescrire Int; 1999 Jun; 8(41):90-5. PubMed ID: 10558453
[TBL] [Abstract][Full Text] [Related]
15. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
16. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
18. Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
McFarlane SI; Provilus A; Shin JJ
J Cardiometab Syndr; 2007; 2(2):149-50. PubMed ID: 17684471
[No Abstract] [Full Text] [Related]
19. [New therapeutic principle in the management of hypertension].
Internist (Berl); 1996 Apr; 37(4 Suppl Neues Ther):1-8. PubMed ID: 9404525
[No Abstract] [Full Text] [Related]
20. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.
Lièvre M; Marre M; Chatellier G; Plouin P; Réglier J; Richardson L; Bugnard F; Vasmant D
Control Clin Trials; 2000 Aug; 21(4):383-96. PubMed ID: 10913814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
